Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers
Launched by GALDERMA R&D · Jun 25, 2010
Trial Information
Current as of September 12, 2025
Completed
Keywords
ClinConnect Summary
The range of fillers tested in this study includes 5 different hyaluronic acid dermal fillers: Emervel Touch, Emervel Classic, Emervel Deep, Emervel Volume and Emervel Lips.
The study will last 6 month.
Injections will be performed at baseline. If necessary, the investigator will perform touch-up injections at the following visit (3 weeks later).
Investigator and subject satisfaction will be collected through questionnaires.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Seeking tissue augmentation treatment on the face,
- • Presenting a score of 3 (Moderately deep wrinkle)or 4 (Deep wrinkle) on the Lemperle Rating Scale (LRS) of both nasolabial folds.
- Exclusion Criteria:
- • At risk in term of precautions, warnings and contra-indication referred in the package insert of the study devices,
- • Who underwent previous injection of permanent filler in the injected area.
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Arras, France
Nice, France
Paris, France
Berlin, Germany
Darmstadt, Germany
Patients applied
Trial Officials
Philippe KESTEMONT
Principal Investigator
Investigational site Nice France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials